Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy

Inclusion Criteria: * Relapsers to previous combination therapy with (PEG-)IFN alfa-/Ribavirin and a negative HCV-RNA test result at the end of this regular treatment course and positive HCV-RNA test result during the follow-up period. * Termination of (PEG-)IFN alfa-/ribavirin therapy at least 3 months prior to enrolment * Chronic HCV infection genotype 1 or 3. * Serum HCV-RNA quantifiable at \>100 IU/mL by COBAS AmpliPrep or another quantitative HCV-RNA PCR test (reported in IU) * Compensated liver disease (Child-Pugh A) * Exclusion of HCC in patients with cirrhosis or transition to cirrhosis. In patients with AFP \>50 ng/mL an established assay for exclusion of HCC has to be done * Negative urine or blood pregnancy test * All fertile males and females must use two reliable forms of effective contraception (combined) during treatment with study drugs and 6 months post treatment Exclusion Criteria (at screening): * Hypersensitiveness to Interferon, PEG-IFN alfa-2a, Ribavirin and Amantadine or other ingredient of the drugs * Ongoing pregnancy or breast feeding * Male partners of women who are pregnant or with women without effective contraception * Signs or symptoms of hepatocellular carcinoma * Chronic HCV infection genotype 2, 4, 5 or 6 * Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment \< 6 months prior to the first dose of study drug and during study period. Exception: patients who have had a limited (\< 7 days) course of acyclovir or valacyclovir for herpetic lesions \< 1 month prior to the first administration of test drug are not excluded. * Any investigational drug \< 6 weeks prior to the first dose of study drug * Positive test for anti-HAV IgM, HBsAg, anti-HBc IgM, anti-HIV * History or other evidence of a medical condition associated with chronic liver disease other than HCV * History or other evidence of decompensated liver disease or a Child-Pugh score \> 6. * Hb \<12 g/dL (\<120 g/L) in women or \<13 g/dL (\<130 g/L) in men at screening * Any patient with an increased baseline risk for anemia or for whom anemia would be medically problematic * Neutrophil count \<1,500 cells/mm3 and/or platelet count \<90,000 cells/mm3 * Serum creatinin concentration \>1.5 mg/dl * History of severe psychiatric disease, especially depression. * History of a severe seizure disorder that can not be stabilized by medication * History of immunologically mediated disease * Chronic pulmonary disease associated with functional limitation * History of severe cardiac disease * History of major organ transplantation except corneatransplantation * Evidence of severe illness, malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study * Thyroid dysfunction not adequately controlled * Evidence of severe retinopathy or clinically relevant ophthalmological disorder due to diabetes mellitus or hypertension * Evidence of active drug abuse within one year of study entry except of a prescribed stable opioid substitution * Take of Memantine during study period * Cardiomyopathy and myocarditis * AV-Block II° and III° * Pre-existing bradycardia \< 55 counts/min * Known QT-interval (QTc after Bazett \> 420 ms) or recognized U-waves or congenital QT-syndrome * History of severe ventricular arrhythmia incl. Torsade de pointes * Simultaneous therapy with Budipin or other medicine that extend the QT-interval like (e.g.antiarrhythmic drugs class IA and class III, antipsychotic drugs, tri- and tetracyclic antidepressants, antihistaminics, macrolide, gyrase inhibitors, Azol-antimykotics) * Patients with obstructive glaucoma * Patients with excitableness and confusion * Patients with delirium and exogenic psychosis in the anamnesis * Prostataadenome * Diuretic medication of the type combination Triamterene/ Hydrochlorothiazide * Inability or unwillingness to provide informed consent or abide by the requirements of the study